ELV 10-K Analysis: The $199B Growth Trap Behind Flat Earnings

Elevance Health, the second-largest U.S. health insurer with $199 billion in revenue, grew its top line by $22.1 billion in FY 2025 — and lost $663 million in operating income doing it. For every dollar of new revenue, ELV destroyed three cents of operating profit. Yet reported EPS barely moved, falling just 1.8% to $25.21.

The headline numbers tell a growth story. Revenue surged 12.5% to $199.1 billion. The company holds exclusive Blue Cross Blue Shield licenses in 14 states — a franchise moat that no competitor can replicate. At 13.9x trailing earnings, the stock looks like a discount play on managed care's largest platform. And management's FY 2026 guidance of approximately $25.50 adjusted EPS implies stability.

But the 10-K, filed February 6, 2026, reveals why that stability is an illusion. Operating expenses grew 13.8% — outpacing revenue by 130 basis points — and a three-layer earnings mask concealed what was really a roughly 15% operational decline. A non-recurring 880-basis-point tax rate collapse added $593 million to net income. A $666 million prior-year settlement should have been a tailwind yet was fully absorbed by cost deterioration. And $2.6 billion in buybacks — funded partially by debt — cushioned EPS by $0.74 per share. Strip all three layers, and the stock trades at 15.5x normalized earnings, not the 13.9x that appears on screen. Meanwhile, a $3.9 billion financial exposure to a PE-backed joint venture — five times the headline figure — sits in the footnotes.

The $22 Billion Growth Trap

Revenue growth is supposed to create value. For Elevance Health in FY 2025, it did the opposite. Revenue grew $22.1 billion (+12.5%) to $199.1 billion, but operating income fell $663 million (-8.4%) to $7,199 million because operating expenses grew faster — up 13.8% to $192.4 billion. The result: an incremental operating margin of -3.0%, calculated as the change in operating income divided by the change in revenue [($7,199M - $7,862M) / ($199,125M - $177,011M)].

The filing is direct about the cause. ELV attributes the margin compression to "higher medical cost trend across all lines of business within our Health Benefits segment, principally within our ACA business." This is not a one-quarter aberration — medical cost trends outpaced premium rate increases across the entire fiscal year.

"Our benefit expense ratio increased primarily as a result of higher medical cost trend across all lines of business within our Health Benefits segment, principally within our ACA business."

But the reported -8.4% operating income decline understates the problem. In FY 2024, ELV recorded a $666 million charge for its share of the Blue Cross Blue Shield Association provider settlement. That charge depressed FY 2024 operating income, meaning FY 2024 operating income on a settlement-adjusted basis was $8,528 million ($7,862M + $666M). The non-recurrence of this charge in FY 2025 should have provided an equivalent tailwind. Instead, operating income still fell. The true operational decline — FY 2025's $7,199 million versus settlement-adjusted FY 2024's $8,528 million — was -15.6%, nearly double the reported figure.

Management's FY 2026 guidance of approximately 90.2% benefit expense ratio (±50bp) confirms this trend is not moderating. Each 10 basis points of BER movement translates to roughly $170 million of operating income on ELV's premium base. And the expiration of enhanced Premium Tax Credits on December 31, 2025 introduces a new wildcard: if price-sensitive healthy members disenroll from ACA exchanges, the remaining risk pool skews sicker — precisely the adverse selection spiral that pushes BER higher.

Elevance Health's incremental operating margin was -3.0% in FY 2025, meaning every dollar of the company's $22.1 billion in revenue growth destroyed three cents of operating profit as medical cost trends outpaced premium rate increases.

Three Layers of Earnings Flattery

The operating deterioration was severe. So why did reported EPS decline just 1.8%, from $25.68 to $25.21? Because three independent mechanisms — none of them operational — combined to mask the true trajectory. This is what we call the Three-Layer Earnings Mask, and decomposing it reveals the distance between headline EPS and operational reality.

Layer 1: The Tax Windfall. The effective tax rate collapsed from 24.5% (FY 2024) to 15.6% (FY 2025) — an 880-basis-point decline. Current state and local taxes plummeted 71%, from $448 million to $128 million. Current federal taxes fell 43%, from $1,753 million to $1,000 million. The filing attributes this to "certain investment credits" but discloses nothing about the type, size, or expected duration of these credits. At FY 2024's 24.5% tax rate, net income would have been approximately $5,069 million [$6,710M pretax × (1 - 0.2446)] rather than the reported $5,662 million — a $593 million difference. That windfall added roughly $2.65 per diluted share to reported EPS.

Layer 2: The Settlement Absorption. The $666 million BCBSA provider settlement from FY 2024 did not recur. This should have been a clean tailwind to operating income. Instead, the entire benefit was absorbed by the acceleration in medical cost trends, leaving operating income lower than the prior year despite the non-recurrence. The settlement mask does not appear in the income statement — it is visible only by comparing the trajectory of costs with and without the prior-year charge.

Layer 3: The Buyback Cushion. Share count fell 3.0%, from 227.5 million to 220.7 million, as ELV spent $2,605 million on buybacks. This mechanical reduction cushioned EPS by approximately $0.74 per share [$25.21 - ($5,662M / 227.5M shares)]. The problem: the buybacks exceeded free cash flow by $960 million, meaning ELV borrowed to shrink its float.

"Our operating expense ratio decreased primarily due to operating leverage associated with growth in operating revenue and non-recurrence of the BCBSA provider settlement."

Note the dissonance: management highlights a ratio that decreased while the absolute operating income declined 8.4% — and 15.6% on a settlement-adjusted basis. The operating expense ratio can improve while profits fall if revenue is growing fast enough, which is exactly what happened. It is a technically accurate statement that obscures the deterioration visible in every absolute-dollar metric.

For context, ELV's 2.84% net margin is thin by any standard but particularly notable within managed care, where UnitedHealth Group typically operates at 4-5% and Cigna at approximately 3.2%. The margin compression is not an industry-wide phenomenon — it is ELV-specific, driven by the intersection of ACA cost pressure and a cost structure that is not scaling.

Elevance Health's reported EPS decline of -1.8% conceals a roughly 15% operational earnings decline, masked by a non-recurring 880-basis-point tax rate collapse that added $593 million to net income in FY 2025.

The Cash Conversion Cliff

If the earnings mask raises questions about income quality, the cash flow statement answers them. Operating cash flow fell 26.1% — from $5,808 million to $4,290 million — while net income fell only 5.3%. That 4.9:1 divergence ratio compressed the OCF/NI ratio from 0.97x to 0.76x, meaning Elevance Health generated only 76 cents of cash for every dollar of reported profit. The 8-quarter trend shows this is accelerating, not mean-reverting.

The deterioration has immediate consequences for capital allocation. In FY 2025, ELV returned $4,134 million to shareholders — $2,605 million in buybacks and $1,529 million in dividends. Free cash flow (OCF minus $1,116 million in CapEx) was $3,174 million, leaving a $960 million deficit. Capital returns consumed 96.4% of operating cash flow ($4,134M / $4,290M). This was a reversal from FY 2024, when FCF of $4,552 million fully covered $4,406 million in returns with room to spare.

How did ELV fund the gap? Partly through a September 2025 debt issuance: $3 billion in new notes at a weighted average rate of 4.73% [$750M at 4.0% + $750M at 4.6% + $1,000M at 5.0% + $500M at 5.7%]. This replaced $1,649 million in maturing bonds, producing approximately $1.35 billion in net new debt. Interest coverage eroded from 6.63x to 5.13x ($7,199M operating income / $1,402M interest expense) as a result.

Beneath the cash flow line, reserve dynamics add another layer of concern. Favorable prior year reserve development — the amount by which prior-year claims came in below estimates — declined from $1,610 million to $1,266 million. More importantly, the composition shifted: completion factors collapsed 76%, from $946 million to $231 million, while trend factor development rose from $664 million to $1,035 million.

"The favorable development recognized in the nine months ended September 30, 2025 resulted from trend factors in late 2024 developing more favorably than originally expected as well as a smaller contribution from faster than expected development of completion factors from the latter part of 2024."

Translation: claims from late 2024 came in below cost expectations (good), but claims are taking longer to process and complete (bad). When completion factors collapse, it means the lag between incurred claims and final settlement is extending — a sign that the claims environment is growing more complex and current-year reserves may be less adequate than actuarial models assume.

Elevance Health's capital returns of $4.1 billion consumed 96.4% of operating cash flow in FY 2025, exceeding free cash flow by $960 million and forcing reliance on debt issuance to fund shareholder returns.

The $3.9 Billion Shadow Bet

Mosaic Health appears in the 10-K as a $732 million related-party transaction. The filing tells a different story. Mosaic Health — formally Augusta Topco Holdings, L.P. — is a joint venture between Elevance Health (~40% ownership) and Clayton, Dubilier & Rice (CD&R), a private equity firm. It was formed in August 2024, combining Carelon's CMSI Assets, apree health, and Millennium Physician Group into a care delivery platform.

The headline $732 million is the annual services expense. The full financial commitment is approximately $3.9 billion — 8.8% of total equity — spread across multiple layers: $2,880 million in equity ($2,580M initial investment plus $300M CMSI asset contribution), a $200 million term loan, a $500 million credit facility ($100 million drawn as of year-end), and a $70 million no-equity funding commitment through December 2026. The $70 million commitment is notable: ELV committed to inject capital for no additional equity interest, meaning shareholders absorb downside without proportional upside.

"During the year ended December 31, 2025, related party transactions with Mosaic Health included care delivery and enablement services to Elevance Health subsidiaries amounting to $732, reported in benefit expense. Care delivery and enablement services provided by Mosaic Health in 2024 were not material."

"We committed to providing $70 of funding for no additional equity interest in Mosaic Health to meet any shortfall in operating cash flow and regulatory capital requirements of the CMSI Assets through December 31, 2026."

The Mosaic structure means ELV is simultaneously equity investor, lender, customer, and contingent guarantor to an entity it does not control. The JV partner, CD&R, is a private equity firm — and PE exit timelines create valuation uncertainty that is difficult to model.

This opacity extends to the broader financial statements. The filing's revenue recognition policy for Medicaid contracts contains a structural asymmetry: premium rate increases from government agencies are deferred until rates are finalized, but premium rate decreases "are recognized in the period the change in premium rate becomes effective and the change in the rate is known, which may be prior to the period when the contract amendment affecting the rate is finalized." Bad news hits the income statement immediately; good news waits.

"Premium rate decreases are recognized in the period the change in premium rate becomes effective and the change in the rate is known, which may be prior to the period when the contract amendment affecting the rate is finalized."

In a Medicaid redetermination environment where states are slow to finalize rate increases, this policy can compress reported margins below underlying economics — or, viewed differently, it means any margin recovery from rate increases will arrive later than the cost deterioration that preceded it. Either way, forward earnings predictability suffers.

Meanwhile, Carelon Services — ELV's vertical integration bet — accumulated $1.7 billion in new goodwill over 18 months (from $2,256 million in January 2024 to $3,994 million in December 2025), suggesting acquisition-driven rather than organic growth. The segment generates $28.3 billion in revenue at only 3.4% operating margin, with most revenue coming from intercompany transactions. The departure of the Carelon Services president, with the CFO absorbing oversight duties, adds a leadership vacuum to the strategic question of whether this vertical integration creates standalone value.

Elevance Health's total financial exposure to Mosaic Health is approximately $3.9 billion — 8.8% of total equity — making the company simultaneously equity investor, lender, customer, and guarantor to a PE-backed entity it does not control.

What to Watch

The thesis — that ELV's revenue growth is operationally value-destructive, masked by three non-recurring tailwinds — will be tested by three observable metrics in 2026. Q1 2026 earnings, expected in mid-April, will provide the first data points.

1. Benefit Expense Ratio. Management guided 90.2% ±50bp for FY 2026. If Q1 BER exceeds 90.5%, the full-year target is at risk and the cost spiral thesis is confirmed. If BER falls below 89.5%, it signals that ACA cost trends are moderating faster than expected — a bullish inflection point. Each 10bp of BER = approximately $170 million of operating income.

2. Effective Tax Rate. The 15.6% FY 2025 rate was 880bp below the prior year. If FY 2026 ETR normalizes toward 21-24%, EPS faces a $2-3 per share headwind. If it stays near 15-16%, the investment credits may be more durable than the magnitude suggests — which would make the FY 2025 number less anomalous but still leave the operating deterioration unaddressed.

3. OCF/NI Ratio. The 0.76x ratio is a cash quality signal. If it recovers above 0.90x in Q1, the FY 2025 deterioration was likely timing-related (working capital normalization). If it stays below 0.80x, the cash conversion deficit is structural, and the buyback program either decelerates or continues consuming debt capacity.

The three scenarios frame the valuation question:

At $350.55, the market prices ELV at 13.9x reported FY 2025 earnings — which implies 4-5% annual EPS growth to justify a terminal value at a market-average multiple. But at 15.5x normalized earnings ($350.55 / $22.56 tax-adjusted EPS), the implied growth rate rises to 6-7% annually. The filing shows revenue growing 12.5% while operating income fell 15.6% on a settlement-adjusted basis. For normalized EPS growth of 6-7%, ELV needs either sustained tax benefits, material BER improvement, or revenue growth that translates to positive operating leverage — none of which the filing supports.

The thesis breaks if all three recovery conditions are met by Q1 2026: BER below 89.5%, ETR below 17%, and OCF/NI above 0.90x. If only two of three recover, the thesis survives pending H2 data. At $350, the filing supports the view that investors are buying a cost spiral disguised as growth — but complicates it with the possibility that tax credits prove more durable than their magnitude suggests.

Frequently Asked Questions

What does Elevance Health's FY 2025 10-K reveal about earnings quality?

The filing reveals that Elevance Health's reported EPS decline of -1.8% ($25.68 to $25.21) dramatically understates the operational deterioration. Three independent, largely non-recurring factors masked the true picture: (1) the effective tax rate collapsed from 24.5% to 15.6%, adding $593 million to net income — driven by undisclosed "investment credits" and a 71% state tax implosion; (2) the non-recurrence of a $666 million BCBSA provider settlement should have boosted operating income, but costs absorbed the entire tailwind; (3) 3.0% share count reduction from $2.6 billion in buybacks cushioned EPS by approximately $0.74. At a normalized tax rate, EPS would have been approximately $22.56 — a 12% decline, not 1.8%.

Why did Elevance Health's operating income fall despite 12.5% revenue growth?

Revenue grew $22.1 billion to $199.1 billion (+12.5%), but operating income declined $663 million to $7,199 million (-8.4%) because operating expenses grew faster (13.8%) than revenue. The filing attributes this to "higher medical cost trend across all lines of business within our Health Benefits segment, principally within our ACA business." The incremental operating margin was -3.0%, meaning every dollar of growth destroyed three cents of operating profit. Adjusting for the BCBSA settlement non-recurrence ($666 million), the underlying operational decline was approximately -15.6%.

What is the Mosaic Health related-party transaction and why does it matter?

Mosaic Health (formally Augusta Topco Holdings, L.P.) is a joint venture between Elevance Health (~40% stake) and Clayton, Dubilier & Rice (CD&R), a private equity firm. It combines CMSI Assets, apree health, and Millennium Physician Group. In FY 2025, ELV paid Mosaic Health $732 million for care delivery services — up from "not material" in FY 2024. But the total financial exposure is approximately $3.9 billion (8.8% of total equity): $2,880 million in equity, a $200 million term loan, a $500 million credit facility ($100 million drawn), a $70 million no-equity funding commitment, and $732 million in annual services. ELV is simultaneously equity investor, lender, customer, and guarantor to an entity it does not control.

How sustainable is Elevance Health's dividend and buyback program?

In FY 2025, total capital returned was $4,134 million ($2,605 million in buybacks plus $1,529 million in dividends). Free cash flow was only $3,174 million, creating a $960 million deficit funded by net debt issuance and existing cash. Capital returns consumed 96.4% of operating cash flow. This was a reversal from FY 2024, when FCF of $4,552 million fully covered returns. With OCF declining 26.1% and the OCF/NI ratio deteriorating from 0.97x to 0.76x, the current pace of capital returns is unsustainable without either OCF recovery or continued debt issuance.

What happened to Elevance Health's effective tax rate in FY 2025?

The effective tax rate dropped from 24.5% (FY 2024) to 15.6% (FY 2025) — an 880 basis point decline. The component breakdown: current state and local taxes collapsed 71% ($448 million to $128 million), while current federal taxes fell 43% ($1,753 million to $1,000 million). Combined current tax savings totaled $1,073 million. The filing attributes this to "certain investment credits" without specifying type or duration. This benefit added approximately $593 million to net income, or about $2.65 per diluted share. Whether these credits are durable (potentially Inflation Reduction Act-related) or one-time will determine whether FY 2026 EPS faces a multi-dollar headwind from tax normalization.

How does Elevance Health's profitability compare to peers?

Elevance Health's 2.84% net margin is structurally lower than financial sector peers: TD (30.3%), SCHW (27.9%), and C (15.3%). This gap reflects the managed care model, where 85-90% of revenue passes through as benefit expense. Within managed care, ELV's margin is below UnitedHealth Group's typical 4-5% net margin and roughly in line with Cigna's approximately 3.2%. ELV's ROE (13.3%) is mid-pack versus the 6-17% range among financial sector peers, but its goodwill ($28.3 billion, 64.6% of equity) means tangible equity is only $4.3 billion — making tangible return comparisons less meaningful.

What are the CMS Medicare Advantage enrollment sanctions?

On February 27, 2026 — after the 10-K was filed February 6 — CMS imposed intermediate sanctions on Elevance Health for "substantial and persistent" noncompliance with Medicare Advantage data submission requirements. ELV had submitted risk adjustment data via physical flash drives instead of electronic systems for seven consecutive years despite repeated warnings. The enrollment freeze took effect March 31, 2026, blocking all new MA enrollments until the violation is corrected. This is compounded by the filing's disclosure that 41% of MA membership is in plans rated below 4.0 Stars, which do not qualify for CMS quality bonus payments in 2027.

What does the OCF/NI ratio collapse mean for investors?

The operating cash flow to net income ratio declined from 0.97x (FY 2024) to 0.76x (FY 2025), meaning ELV generated only 76 cents of cash for every dollar of reported net income. OCF fell 26.1% ($5,808 million to $4,290 million) while net income fell only 5.3% — a 4.9:1 divergence. This suggests working capital pressures (rising claims payable timing, reserve building) that GAAP earnings do not capture. For investors, cash conversion is the early-warning signal: if earnings quality is deteriorating, reported EPS overstates the company's ability to fund dividends, buybacks, and debt service from operations.

Is Elevance Health's benefit expense ratio getting worse?

Yes. The filing explicitly states that the benefit expense ratio "increased primarily as a result of higher medical cost trend across all lines of business within our Health Benefits segment, principally within our ACA business." Management has guided to a 90.2% ±50bp benefit expense ratio for FY 2026. Each 10 basis points of BER movement represents approximately $170 million in operating income. The expiration of enhanced Premium Tax Credits on December 31, 2025 could worsen the risk pool as price-sensitive healthy members disenroll from ACA exchanges, concentrating higher-cost members.

What is the BCBSA provider settlement and how does it affect FY 2025 results?

The Blue Cross Blue Shield Association provider settlement resulted in a $666 million non-recurring charge in FY 2024, depressing that year's operating income. Its non-recurrence in FY 2025 should have created an equivalent tailwind. Yet FY 2025 operating income still declined $663 million (-8.4%). This means the underlying operational deterioration was approximately $1,329 million [$663M reported decline + $666M lost tailwind], or -15.6% versus settlement-adjusted FY 2024 operating income of $8,528 million ($7,862M + $666M). This is the single most important adjustment for understanding ELV's true operational trajectory.

How much of Carelon's growth is from acquisitions vs. organic?

Carelon Services accumulated $1.7 billion in new goodwill over 18 months (from $2,256 million in January 2024 to $3,994 million in December 2025), indicating aggressive M&A-driven growth. The segment generates $28.3 billion in revenue at only 3.4% operating margin, with most revenue from intercompany transactions with ELV's own health plans. The goodwill trajectory and the departure of the Carelon Services president raise questions about whether the vertical integration strategy creates standalone value or simply transfers costs between segments. At current margins, the $4.0 billion in goodwill implies a 24% return on invested goodwill — adequate but uncompelling for an acquisition-dependent business.

What are the key risks for ELV stock in 2026?

The filing and post-filing events identify five principal risks: (1) Medical cost trend continuation — if ACA benefit expense ratios remain elevated, operating margins will continue compressing despite revenue growth; (2) Tax rate normalization — if the 15.6% ETR reverts toward 24.5%, EPS faces a roughly $2.65/share headwind; (3) CMS enrollment sanctions — if not resolved before October 2026 AEP, Medicare Advantage membership growth is blocked; (4) Enhanced PTC expiration — individual exchange enrollment could decline as subsidized members face higher premiums; (5) Capital return sustainability — if OCF does not recover, the $4.1 billion annual return program requires continued debt issuance, further pressuring interest coverage (already down from 6.63x to 5.13x).

Methodology

Data Sources

This analysis uses three data sources, each tagged for traceability:

• MetricDuck Metrics Pipeline [PIPELINE]: Core financial metrics (income statement, balance sheet, cash flow, returns, valuation) from automated SEC filing extraction for ELV, TD, C, SCHW, and LARK. Available at ELV Analysis.
• SEC 10-K Filing [FILING]: Verbatim quotes and detailed disclosures from Elevance Health's FY2025 Annual Report, including MD&A, footnotes on income taxes, related-party transactions, revenue recognition, goodwill, and debt.
• Derived Calculations [DERIVED]: 26 formulas documented in research notes, each with source data and reproducible computation (e.g., incremental operating margin, tax-adjusted net income, settlement-adjusted operating income decline, Mosaic total exposure).

Limitations

• Peer set mismatch. The assigned peers (TD, C, SCHW, LARK) are financial sector companies, not managed care companies. The comparison provides cross-sector context but cannot isolate whether ELV's margin compression is company-specific or industry-wide. Managed care peers (UNH, CI, HUM) are referenced qualitatively where relevant but lack equivalent pipeline depth.
• Benefit expense ratio by line of business. The filing confirms ACA is the primary BER pressure point but does not provide segment-level BER breakdowns. We cannot quantify how much of the increase is attributable to ACA versus Medicaid versus Commercial.
• Tax credit durability unknown. The filing attributes the 880bp ETR decline to "certain investment credits" without specifying type, size, or expected duration. Our analysis assumes non-recurrence based on magnitude, but IRA-related credits could persist in reduced form.
• CMS sanctions are post-filing. The February 27, 2026 enrollment sanctions post-date the February 6 10-K filing. The filing's risk factors warn of data submission risks but do not disclose the flash-drive practice. Post-filing events are separated from filing-derived findings throughout.
• Carelon intercompany eliminations not fully quantifiable. Exact elimination amounts between Health Benefits, CarelonRx, and Carelon Services are partially visible in segment tables but not fully parseable. The goodwill analysis provides a proxy for acquisition dependency but not a precise third-party revenue figure.
• Membership data not available. Exact membership counts by line of business are embedded in filing tables not cleanly extractable from the current API. Directional trends are confirmed from filing text.

Disclaimer:

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in ELV, TD, C, SCHW, or LARK. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process.